Technical Analysis for ARGX - argenx SE
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 1.29% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.29% | |
| Bollinger Band Squeeze | Range Contraction | 1.29% | |
| Inside Day | Range Contraction | 1.29% | |
| Gapped Up | Strength | 1.29% | |
| Fell Below 20 DMA | Bearish | 2.61% | |
| New Downtrend | Bearish | 2.61% | |
| Bollinger Band Squeeze | Range Contraction | 2.61% | |
| Bollinger Band Squeeze | Range Contraction | -0.39% | |
| Outside Day | Range Expansion | -0.39% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 6 hours ago |
| 10 DMA Resistance | about 6 hours ago |
| Non-ADX 1,2,3,4 Pullback Entry | about 6 hours ago |
| Rose Above Previous Day's High | about 6 hours ago |
| Rose Above 10 DMA | about 6 hours ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
argenx SE Description
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Disease Cancer Immunotherapy Inflammation Acute Myeloid Leukemia Lymphoma Lipid Rheumatoid Arthritis Myelodysplastic Syndrome Treatment Of Autoimmune Disease Myasthenia Gravis Dyslipidemia Hematological Cancers Myasthenia Thrombocytopenia Skin Inflammation Janus Kinase Inhibitor Rgx Therapies For The Treatment Of Autoimmune Diseases Treatment Of Hematological Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 554.74 |
| 52 Week Low | 327.73 |
| Average Volume | 309,424 |
| 200-Day Moving Average | 421.77 |
| 50-Day Moving Average | 508.81 |
| 20-Day Moving Average | 528.63 |
| 10-Day Moving Average | 537.85 |
| Average True Range | 11.73 |
| RSI (14) | 53.27 |
| ADX | 23.78 |
| +DI | 25.39 |
| -DI | 26.61 |
| Chandelier Exit (Long, 3 ATRs) | 519.55 |
| Chandelier Exit (Short, 3 ATRs) | 546.38 |
| Upper Bollinger Bands | 551.06 |
| Lower Bollinger Band | 506.19 |
| Percent B (%b) | 0.51 |
| BandWidth | 8.49 |
| MACD Line | 7.48 |
| MACD Signal Line | 9.92 |
| MACD Histogram | -2.4383 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 540.36 | ||||
| Resistance 3 (R3) | 540.71 | 537.30 | 538.47 | ||
| Resistance 2 (R2) | 537.30 | 534.42 | 537.12 | 537.84 | |
| Resistance 1 (R1) | 533.18 | 532.65 | 535.24 | 532.83 | 537.22 |
| Pivot Point | 529.77 | 529.77 | 530.80 | 529.59 | 529.77 |
| Support 1 (S1) | 525.65 | 526.89 | 527.71 | 525.30 | 520.90 |
| Support 2 (S2) | 522.24 | 525.12 | 522.06 | 520.28 | |
| Support 3 (S3) | 518.12 | 522.24 | 519.65 | ||
| Support 4 (S4) | 517.77 |
